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Summary
Patients with multiple schwannomas without vestibular
schwannomas have been postulated to compose a dis-
tinct subclass of neurofibromatosis (NF), termed
“schwannomatosis.” To compare the molecular-genetic
basis of schwannomatosis with NF2, we examined the
NF2 locus in 20 unrelated schwannomatosis patients
and their affected relatives. Tumors from these patients
frequently harbored typical truncating mutations of the
NF2 gene and loss of heterozygosity of the surrounding
region of chromosome 22. Surprisingly, unlike patients
with NF2, no heterozygousNF2-gene changes were seen
in normal tissues. Examination of multiple tumors from
the same patient revealed that some schwannomatosis
patients are somatic mosaics for NF2-gene changes. By
contrast, other individuals, particularly those with a pos-
itive family history, appear to have an inherited predis-
position to formation of tumors that carry somatic al-
terations of the NF2 gene. Further work is needed to
define the pathogenetics of this unusual disease
mechanism.
Introduction
Schwannomas are benign tumors of the peripheral nerve
sheath that usually occur singly in otherwise normal in-
dividuals. Multiple schwannomas in the same individual
suggest an underlying tumor-predisposition syndrome.
The most common such syndrome is neurofibromatosis
2 (NF2) (see Appendix). The hallmark of NF2 is the
development of bilateral vestibular-nerve schwannomas;
but two-thirds or more of all NF2-affected individuals
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develop schwannomas in other locations, and dermal
schwannomas may precede vestibular tumors in NF2-
affected children (Evans et al. 1992;Mautner et al. 1993;
Parry et al. 1994). Recently, there have been several re-
ports of individuals with multiple schwannomas who do
not show evidence of vestibular schwannoma (summa-
rized in MacCollin et al. 1996). Our previous clinical
report suggests that schwannomatosis is a clinical entity
distinct from other forms of neurofibromatosis (NF)
(MacCollin et al. 1996); however, its molecular-genetic
basis remains unclear.
The NF2 gene was cloned in 1993, both by our own
group and by others, and was found to encode a 595-
amino-acid member of the ezrin-radixin-moesin family
of cytoskeleton-associated proteins (Rouleau et al. 1993;
Trofatter et al. 1993). As with other members of this
family of proteins, the NF2 protein product has been
found to localize in motile regions of the cell, such as
in leading and ruffling edges (Arpin et al. 1994; Gon-
zalez-Agosti et al. 1996). Mutational analysis of theNF2
gene in typical NF2 patients (i.e., those with bilateral
vestibular schwannomas) has demonstrated causative
mutation in as many as two-thirds of individuals
(MacCollin et al. 1994; Parry et al. 1996; Ruttledge et
al. 1996). Many studies have documented that the NF2
gene behaves as a typical tumor-suppressor gene in these
patients, with first hits detectable in both constitutional
and tumor specimens and with second hits detectable
only in tumors (Rouleau et al. 1993; Bijlsma et al. 1994;
Jacoby et al. 1994, 1996). Studies of sporadic schwan-
nomas and meningiomas have also supported the two-
hit model (Bijlsma et al. 1994; Jacoby et al. 1994, 1996;
Wellenreuther et al. 1995). In both sporadic and NF2-
associated tumors, second hits often involve deletion of
all or a large portion of chromosome 22, causing loss
of heterozygosity (LOH) of flanking and intragenic poly-
morphic markers.
In a single study, germ-line inactivation of the NF2
gene had been detected in two patients of Japanese ex-
traction, with multiple intradermal schwannomas, who
were reported not to have vestibular tumors (Honda et
al. 1995). A third patient without vestibular tumors,
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who carried a germ-line splice-site mutation of the NF2
gene, had been reported to have bilateral facial-nerve
schwannomas (Rouleau et al. 1993). The purpose of the
current study was to determine the extent to which the
NF2 tumor-suppressor gene participates in the patho-
genetics of schwannoma formation in a larger cohort of
schwannomatosis patients and their relatives.
Subjects and Methods
Subjects
Individuals and families meeting our criteria for
schwannomatosis (see Appendix) were recruited from
referrals to our ongoing studies of the molecular-genetic
basis of NF2 and from the Neurofibromatosis Clinic at
Massachusetts General Hospital. All patients were asked
about a history of brain tumor, spinal cord tumor, skin
tumor, or unexplained deafness or neurological disability
in all first- and second-degree relatives. Relatives having
or suspected of having any of these conditions were then
also invited to participate. Patients 1–14 were included
in a previous clinical report (MacCollin et al. 1996).
Patient 4 is the subject of a separate case report
(MacCollin et al. 1997b), and a single tumor (S125)
from this patient was included in the study by Jacoby
et al. (1996). To our knowledge, the remainder of the
patients have not been reported elsewhere. This study
was approved by the institutional review board of the
Massachusetts General Hospital, and informed consent
was obtained from all patients and participating family
members.
Specimen Collection
Lymphoblast lines were established from peripheral
blood samples, as described elsewhere (Anderson and
Gusella 1984). Excess tissue was collected at the time
of diagnostic or therapeutic procedures, after patholog-
ical studies were complete. High-molecular-weightDNA
was extracted from peripheral blood leukocytes, cul-
tured lymphoblasts, and frozen pulverized tumor tissue,
by SDS–proteinase K digestion followed by phenol and
chloroform extractions (Jacoby et al. 1996). When fresh
tissue was unavailable, paraffin-embedded blocks were
obtained from pathology-department archives. Ten 3-
micron-thick slices were shaved from the block, and the
surrounding paraffin was solubilized with xylenes. Ex-
cess xylene was removed with ethanol, and the tissue
was digested for 24–48 h with proteinase K. After de-
activation by boiling, the supernatant then was used
without further extraction steps.
Mutational Analysis of the NF2 Gene
SSCP analysis of tumor specimens was performed as
described elsewhere (Jacoby et al. 1996). In brief, the
17 known exons of the NF2 gene were amplified from
genomic DNA. Products were diluted in formamide-con-
taining buffers and were separated on nondenaturing
polyacrylamide gels. Aberrant mobility of single- or dou-
ble-stranded products was identified by comparisonwith
known positive and negative controls. When aberrations
were detected by SSCP, the sequence basis was deter-
mined by direct sequencing using the dideoxy-chain-ter-
mination method. In the case of complex insertions or
deletions, or of alterations near amplification primers,
the exact sequence of the change was determined by T-
vector cloning. For all cases in which an aberration was
detected by SSCP, the matching lymphoblastic DNA
specimen then was amplified for that exon and was run
side by side with the tumor. Because low-level mosaicism
occasionally may be more apparent by direct sequencing
than by SSCP (L. B. Jacoby, unpublished data), the lym-
phoblastic specimens then were reamplified for altered
exons and were sequenced side by side with the tumor.
LOH and Linkage Analysis
Genomic DNA was amplified by use of primer pairs
from two polymorphic microsatellite markers proximal
to NF2, D22S193 (Genome Database, version 5.6) and
D22S275 (Weissenbach et al. 1992); one intragenic
marker, D22S929 (Bourn and Strachan 1995); and two
markers distal to NF2, D22S268 (Marineau et al. 1993)
and D22S430 (Sainz et al. 1993). PCR products were
analyzed as reported elsewhere (Jacoby et al. 1996).
Two-point LOD scores were calculated by use of the
computer program FASTLINK.
Results
Clinical Characteristics of Subjects
A total of 20 unrelated individuals meeting our clinical
criteria for definite or probable schwannomatosis, from
whom one or more tumor specimens were available for
analysis, were identified (table 1). Their ages at onset of
symptoms were within the range of 11–50 years. There
were 9 women and 11 men. Three patients had localized
disease confined to one limb, and three patients had
disease confined to the spinal cord and roots. The pre-
dominant symptom in most patients was pain, which in
many cases was disabling. Contrast-enhanced cranial
magnetic-resonance imaging (MRI) was performed in 15
of 20 patients and revealed no evidence of vestibular
tumor. Noncontrast cranial MRI was normal in patients
25, 26, and 29. Patients 18 and 22 did not undergo
cranial imaging but had no symptoms of hearing or bal-
ance dysfunction at ages 50 years and 80 years, respec-
tively. Ocular findings in patients 1–14 have been re-
ported elsewhere (MacCollin et al. 1996); other patients
did not have routine ophthalmological screening. Pa-
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Table 1
Clinical Characteristics of Patients Studied for This Report
Patient
Age
(years) Sex
Age at Onset
(years) First Symptom Distribution of Tumorsa Affected Relative(s)
1 24 Female 11 Mass, neck Right peripharyngeal
space and jugular
fossa (bilateral)
No
2 33 Female 11 Mass and pain,
foot
Right foot, right wrist,
brachial plexus (bi-
lateral), and thoracic
and lumbar spine
No
3 18 Male 13 Numbness, left 4th
and 5th fingers
Supra- and infraclavicu-
lar, cervical, and
lumbar spine
No
4 19 Male 15 Pain, back Spine and 5th cranial
nerve
No
6 32 Female 17 Pain, arm and
chest
Brachial plexus (bilat-
eral, left more than
right), left chest (in-
tercostal nerve), and
cervical and thoracic
spine (left)
No
7 65 Male 25 Pain, arm Left arm and forearm,
right forearm, thigh
(bilateral), left sural
nerve, right tibial
nerve, and thoracic
and lumbar spine
No
9 39 Female 28 Pain, leg Left leg and foot No
10 35 Female 31 Pain and mass,
arm
Right median nerve No
11 50 Female 33 Pain and mass,
wrist
Right radial nerve No
13 74 Male 49 Tingling, calf Right foot, popliteal
fossa (bilateral), left
posterior tibial nerve,
and sciatic nerve
No
14 54 Female 50 Pain, buttocks and
thigh
Lumbar spine and right
armb
No
15 44 Female 37 Pain, foot Spine and all four
extremities
No
18 83 Female 35 (estimated) Unknown Spine and extremities Yes (granddaughter)
21 39 Male 18 Mass, face Face, arm, and spine Yes (multiple)
22 52 Male 45 Pain, left leg Legs (bilateral) Yes (niece, father)
23 42 Male 30 Pain, back Spine and 5th cranial
nerve (bilateral)
No
24 45 Male 31 Pain, back Spine No
25 48 Male 32 Pain, back Spine No
26 29 Male 11 Skin tumors Spine and skin Yes (multiple)
29 42 Male 40 Asymptomatic Spine Yes (son)
a Includes both surgically removed tumors and those still in place. All patients had multiple tumors, although some (patients 9, 10, 11, 24,
25, and 29) had highly localized disease.
b Pathology not confirmed.
thology reports on 63 separate tumors removed from
these 20 individuals were reviewed, with a diagnosis of
schwannoma (or neurilemmoma, in older cases) given
in 62 of the 63 tumors. A single tumor (of six removed)
from patient 15 was given a pathological diagnosis of
neurofibroma; no further details were stated on the re-
port, and slides were unavailable for review. No patient
had a history of meningioma, ependymoma, or glioma.
Patient 6 previously was reported to have a syndrome
of unexplained weight loss (MacCollin et al. 1996),
which subsequently was found to be due to crack-co-
caine use. HIV testing of this patient was negative on
two occasions.
Five patients gave a positive family history of nervous-
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Figure 1 Typical results of mutational analysis of theNF2 gene.
Results are shown for two tumors from patient 22 in table 1. A, SSCP
analysis. Shifts are seen in exon 2 in tumor 1 and in exon 5 in tumor
2; however, no shift is seen in the paired blood sample. ND  non-
denatured. B, SSCP analysis showing that the sequence basis for the
SSCP shift is a 7-bp deletion in exon 2 and a 1-bp deletion in exon 5
(arrows). Again, no alteration is seen in the paired blood sample. C,
Microsatellite analysis at D22S275. Loss of the same allele in both
tumors is shown. The retained haplotype also was carried by the pa-
tient’s affected niece; a tumor resected from her lost heterozygosity,
retained the shared haplotype, and carried a third sequence alteration
(table 3).
system tumors. Transmission was compatible with au-
tosomal dominant inheritance with incomplete pene-
trance and widely variable expressivity. Eight affected
family members, from four families, agreed to partici-
pation in this study. None of these affected relatives had
a known history of vestibular schwannoma or menin-
gioma, although not all of them had undergone cranial
imaging. A review of five pathology reports on these
eight affected relatives revealed typical features of
schwannoma, for each case.
Mutational Analysis
Mutational analysis of primary tumors from the 20
unrelated probands revealed typical truncating muta-
tions of the NF2 gene in 10 tumors (fig. 1 and table 2).
Mutations included nonsense (three), splice-site altera-
tion (one), and insertion or deletion producing trunca-
tion (six). Alterations were detected throughout the gene,
with a slight predominance in the 5′ exons. None of the
mutations detected in tumor specimens were detected in
the paired lymphoblastic specimens, by use of these
methods.
In eight patients two or more tumors were available
for analysis, and in three patients tumor material was
available from affected family members. These speci-
mens composed a second set of 20 tumors. In these 20
tumors, 12 sequence alterations were detected (table 3).
In two nonfamilial cases (patients 4 and 9), both the
original and subsequent tumors were found to have iden-
tical alterations. In two cases (patients 6 and 25), neither
the original nor subsequent tumors could be found to
have any sequence changes in theNF2 gene. In four cases
(patients 11, 21, 22, and 29), subsequent and familial
tumors were found to have typical truncating mutations
of theNF2 gene; however, these changes were unrelated,
in type or in location, to the mutations seen in the pri-
mary tumors. None of the mutations detected in sub-
sequent tumors were detected in the paired lympho-
blastic specimens, by use of these methods.
Microsatellite Analysis
Microsatellite analysis of the 40 tumors revealed LOH
in 28 tumors (tables 2 and 3). In all cases in which LOH
was seen in 11 tumor from the same individual, the same
allele was lost. Twenty-one of 21 tumors with single
sequence alterations demonstrated LOH, whereas 8 of
18 tumors without detectable sequence alterations dem-
onstrated LOH ( , x2 analysis). The single tumorP ! .005
with two sequence changes retained both alleles, as ex-
pected. Results of microsatellite analysis of three families
were consistent with passage of a single allele to all af-
fected family members and to obligate but nonexpress-
ing carriers (maximum LOD score of 1.611 at ;v  .00
fig. 2). In all three cases, the allele shared by the affected
relatives was also that retained in all tumor specimens.
Discussion
Schwannomas are common, benign tumors of the pe-
ripheral nerve sheath that occur, in their solitary form,
in genetically normal individuals. Multiple schwanno-
mas are most commonly associated with NF2, but many
researchers have suggested that they also may be seen
in a third form of NF, termed “schwannomatosis”
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Table 2
DNA Sequence Alterations and Allele Number in 20 Tumors Derived from Patients with Schwannomatosis
Patienta Sequence Alterationb Codon Changec Consequence Origin LOHd
1 None No
2 None No
3 None No
4 784 CrT (exon 8) Arg262X Nonsense Somatic No
4 233, complex rear-
rangement (exon 2)
Asp78 FS to 122X Frameshift Somatic )
6 None No
7 None No
9 577 ins 4 bp (exon 6) Ala193 FS to 208X Frameshift Somatic Yes
10 None No
11 1021 CrT (exon 11) Arg341X Nonsense Somatic Yes
13 577 ins 8 bp (exon 6)e Ala193 FS to 208X Frameshift Somatic Yes
14 934 ArT (exon 10) Lys312X Nonsense Somatic Yes
15 None No
18 None Yes
21 448–1 grt (exon 5) ) Splice acceptor Somatic Yes
22 205 to 211 del 7 bp
(exon 2)
Lys69 FS to 122X Frameshift Somatic Yes
23 676–3 to 693 del 21 bp
(exon 8)e
) Splice acceptor Somatic Yes
24 None No
25 None Yes
26 1549 ins 29 bp (exon
14)
Leu517 FS to 524X Insertion of stop codon Somatic Yes
29 1–33 to 27 del 60 bp
(exon 1)e
) Deletion of initiation codon Somatic Yes
a Numbering corresponds to that used in table 1.
b Numbering of bases showing alteration is given relative to the cDNA sequence, with the initiator ATG
beginning at base 1. All coding-sequence bases are given in uppercase letters. Alterations affecting an intronic
sequence are given in lowercase letters, and the number following the dash (–) indicates the requisite number
of bases from the first base of the exon. For deletions, the span of deleted bases (numbered as described above)
is given, followed by “del” and the deletion size. An insertion is indicated by “ins” and is followed by the
number of bases inserted.
c The original amino acid and position of the residues in the protein (with the initiator Met numbered as 1)
are followed by “X” for “nonsense mutation” or by “FS” for “frameshift,” followed by the position of the
next in-frame stop codon.
d Determined by flanking and intragenic microsatellite-polymorphism analysis.
e The precise start position of the alteration could not be determined, and therefore the first possible nucleotide
position is given.
(Shishishiba et al. 1984; Purcell and Dixon 1989) (see
Appendix). Others have considered schwannomatosis to
be an attenuated form of NF2 (e.g., see Evans et al. 1997;
Pulst et al. 1997). Several studies have shown that the
NF2 gene is the major tumor suppressor for schwan-
noma, in both sporadic and NF2-associated cases (Rou-
leau et al. 1993; Bijlsma et al. 1994; Jacoby et al. 1994,
1996). In this report, we have demonstrated that the
NF2 gene is inactivated in schwannomas from many
schwannomatosis patients; however, the pattern of in-
activation differs fundamentally from that seen in other
tumor-suppressor syndromes, including that in NF2
itself.
Several case reports of individuals with multiple pe-
ripheral-nerve-sheath tumors have beenmade. For a sub-
set of cases, the pathology has been carefully docu-
mented to be schwannoma, and the diagnoses for these
individuals have been variously termed “schwannoma-
tosis,” “neurilemmomatosis,” or “multiple schwanno-
mas.” We have adopted the term “schwannomatosis”
for clarity in this study. Some of these previous reports
have included patients with unexplained hearing or bal-
ance deficits or individuals who had vestibular schwan-
noma and, thus, had NF2 (e.g., Shishishiba et al. 1984;
Purcell and Dixon 1989; Evans et al. 1997). NF2 also
cannot be excluded in children with multiple schwan-
nomas, since vestibular schwannoma may not be ap-
parent until adolescence (Sasaki and Nakajima 1992).
To our knowledge, there have been no previous reports
of schwannomatosis patients meeting our clinical criteria
who have a positive family history of NF2. Interestingly,
one-third of all previously reported cases of schwan-
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Table 3
DNA Sequence Alterations and Allele Number in Multiple Tumors from Patients with Schwannomatosis
PATIENTa
TUMOR 1b TUMOR 2 TUMOR 3 TUMOR 4
Sequence Alteration LOHc Sequence Alteration LOHc Sequence Alteration LOHc Sequence Alteration LOHc
4 Exon 2, FS; exon 8, NS No Exon 2, FS Yes Exon 2, FS Yes Exon 2, FS Yes
6 None No None No None No ) )
9 Exon 6, FS Yes Exon 6, FS Yes Exon 6, FS Yes ) )
11 Exon 11, NS Yes Exon 3, splice Yes Exon 2, NS Yes ) )
21d Exon 5, splice Yes Exon 8, FS Yes None Yes Nonee Yese
22f Exon 2, FS Yes Exon 5, FS Yes Exon 2, FSe Yese ) )
24 None No Exon 7, splice Yes ) ) ) )
25 None Yes None Yes ) ) ) )
29 Exon 1, deletion Yes Exon 6, NSe Yese ) ) ) )
NOTE.—FS  frameshift; and NS  nonsense mutation.
a Numbering corresponds to that used in table 1.
b Detailed data for each patient are presented in table 2.
c Determined by flanking and intragenic microsatellite-polymorphism analysis.
d Three additional tumors were analyzed; two revealed no sequence alteration and were positive for LOH, and the third revealed no sequence
alteration and no LOH.
e Tumor from affected relative.
f The two exon 2 alterations, found in tumors 1 and 3, were unrelated at a sequence level.
nomatosis have shown anatomical limitation of their
tumors (e.g., see Lewis et al. 1981; Berger et al. 1987;
Buenger et al. 1993).
In our original clinical report (MacCollin et al. 1996)
we documented 14 probands with multiple schwanno-
mas who did not have vestibular tumors, and for this
report we have included an additional 9 probands. These
23 patients differ from NF2 patients in several funda-
mental respects. They have not developed other typical
features of NF2, such as meningiomas (seen in 50% of
NF2 patients) (Evans et al. 1992; Parry et al. 1994) or
ocular pathology (seen in 80% of NF2 patients) (Kaiser-
Kupfer et al. 1989; Bouzas et al. 1993; Ragge et al.
1995). In addition, we have not found a schwannom-
atosis patient who has developed the more unusual man-
ifestations of NF2, such as ependymoma, astrocytoma,
or peripheral neuropathy. Unlike NF2, schwannoma-
tosis is infrequently familial, with affected relatives being
documented for only six of our patients. Finally, when
familial occurrence is seen, incomplete penetrance and
variable expressivity are common, which is in distinct
opposition to NF2, which shows complete penetrance
and relative intrafamilial homogeneity (Evans et al.
1992; Parry et al. 1994). On the basis of this experience,
we conclude that adult patients with multiple patholog-
ically proved schwannomas who have had cranial im-
aging adequate to exclude vestibular schwannoma com-
pose a subclass of NF that is distinct from NF2.
We were able to demonstrate NF2-gene mutations in
a majority of tumors resected from these patients. The
mutations were indistinguishable, by type or by location,
from those seen in sporadic or NF2-associated schwan-
nomas (Jacoby et al. 1994, 1996) and would be pre-
dicted to produce a shortened protein product in all
cases. Unlike for NF2 patients, we were unable to doc-
ument a single instance of germ-line NF2 mutation, as
evidenced by an alteration in a lymphoblastic specimen.
For those individuals in whom no mutational events
were identified in the first tumor studied or in subsequent
tumors, we cannot exclude the possibility of undetected
germ-line NF2 mutation.
Loss of all or most of a chromosome is a common
event in tumor-suppressor-gene syndromes, and we dem-
onstrated frequent LOH of chromosome 22 markers in
tumors from schwannomatosis patients. LOH was
greater in tumors with single sequence alterations (100%
of tumors) than in those without NF2-gene changes
(44% of tumors). Interestingly, LOH also was greater
in the former group of tumors than in those of our pre-
vious studies of sporadic schwannomas with single se-
quence alterations (31 [69%] of 45 tumors) (Jacoby et
al. 1994, 1996) or in those of studies of NF2-associated
schwannomas with single sequence alterations (6 [33%]
of 18 tumors) (Bijlsma et al. 1994; Jacoby et al. 1994,
1996). Because most previously studied tumorswere ves-
tibular in origin, it is unclear if this discrepancy is due
to the anatomical location of these tumors or to the
underlying pathogenetic mechanism of their formation.
Although LOH is hypothesized to be a second hit in
NF2-associated and in sporadic schwannomas, we were
unable to determine by these data if LOH occurs before
or after NF2 sequence changes.
In this study, we were able to analyze more than one
tumor from nine individuals and their kindreds. Analysis
of multiple tumors revealed at least three patterns of
NF2-gene changes. In one individual (patient 6), three
tumors revealed noNF2-gene changes and no LOH. The
lack of either finding in multiple tumors suggests that
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Figure 2 Haplotypes surrounding the NF2 gene, for three families with multiple affected individuals. In each kindred a single haplotype
is seen for all affected individuals and obligate nonexpressing carriers. This haplotype also is retained in tumor specimens that show LOH.
T  tumor; ND  not done; and NI  not informative.
this individual’s disorder is not due to inactivation of
the NF2 gene. This individual is unusual in many re-
spects: she has a highly aggressive disease involving pre-
dominantly the left side of the body, with greater neu-
rological disability than any of our other patients. In
addition, her tumors were found to have a plexiform
pattern (Harkin and Reed 1969). It remains to be seen
if these clinical and pathological characteristics have a
pathogenetic significance in schwannomatosis patients.
In two individuals (patients 4 and 9), we documented
identicalNF2-gene changes in multiple anatomically dis-
tinct tumors. In patient 4, described elsewhere (Mac-
Collin et al. 1997b), we subsequently have determined
that the patient is a somatic mosaic with an extremely
low level of mutation in the lymphocytic lineage. Al-
though other mosaic individuals documented by our
studies have had disease that is more clearly localized
to a hemicranial space (MacCollin et al. 1997a), this
patient’s phenotype illustrates the need to consider mo-
saicism even in individuals with widespread disease. In
patient 9 mosaicism also is suspected, because the disease
is confined to a single limb. However, because each tu-
mor had LOH for all markers studied, we cannot rule
out the possibility of the noncontiguous spread of a sin-
1300 Am. J. Hum. Genet. 61:1293–1302, 1997
gle tumor, as has been seen in multiple-meningioma pa-
tients without family history (Stangl et al. 1997). Further
studies are underway to document the exact breakpoints
of each of the tumors in this patient.
An unusual pattern of alteration was seen in four in-
dividuals (patients 11, 21, 22, and 29). In all four cases,
multiple tumors from the same individuals were each
found to have typical truncating mutation of the NF2
gene; however, in each case, individual tumors had pri-
vate mutations, that is, mutations not shared with other
tumors from the same patient or from family members.
In addition, none of these alterations were present at a
germ-line level, as evidenced by a lack of detection in
paired lymphoblastic specimens. In all four cases, LOH
was seen in tumors both with and without NF2-gene
changes, and all LOH occurred on the same allele for
all tumors in the same individual. Three of these four
individuals had affected family members who shared the
same retained allele in their altered tumors.
This pattern suggests that some individuals with
schwannomatosis have an inherited tendency to for-
mation of tumors that carry somatic alteration of the
NF2 gene. This tendency is biased toward the occurrence
of different mutations in the same, coinherited allele
within a given family, combined with loss of the trans
allele in any given individual. Although the family data
are consistent with linkage of this trait to theNF2 locus,
these studies imply that the primary event in these tu-
mors lies outside the coding region of the NF2 gene.
This pattern of alteration is distinct from that seen in
the majority of NF2 patients who carry germ-line mu-
tation of the NF2 gene, as evidenced by alterations in
nontumorous tissue such as lymphoblasts (MacCollin et
al. 1994; Parry et al. 1996). Interestingly, two recent
reports suggest that NF2 coding-region alterations are
not detected in mild-NF2 families (Parry et al. 1996;
Ruttledge et al. 1996); thus, a common pathogenetic
mechanism between schwannomatosis patients and
mildly affected NF2 patients cannot be excluded, since
large numbers of tumors from the latter group have not
been studied.
Several possible mechanisms may explain these unu-
sual molecular findings. Schwannomatosis patients may
carry a structural abnormality in the region of the NF2
gene, making the locus more susceptible to damage or
less readily repaired following replication errors. Per-
haps more likely, a nearby locus may participate in the
generation of schwannomas, as either a recessively or
dominantly acting element. Inherited alterations of this
second locus may predispose to proliferation with sec-
ondary changes in the NF2 locus, enabling true schwan-
noma formation. Frequent LOH in these tumors sup-
ports a cellular-recessive model, since LOHmay function
to remove simultaneously both theNF2 gene and a con-
tiguous second locus. To our knowledge, this is the first
report of an inherited human disease involving the so-
matic accumulation of mutations at a single locus. Fur-
ther work is underway to determine the exact germ-line
basis of this tendency.
In summary, this study supports our previous conclu-
sion that schwannomatosis is a third major form of NF,
with fundamental clinical and genetic differences from
NF2. Unexpectedly, we have found at least two path-
ogenetic mechanisms that cause this phenotype, includ-
ing mosaic alteration at the NF2 locus and somatic ac-
cumulation of NF2-gene mutations. Our data also
suggest that a non-NF2 locus may be implicated in a
third, small group of patients. Further studies are needed
to determine if clinical differences exist between these
genetic subpopulations of patients.
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Appendix
Proposed Diagnostic Criteria
NF2
Definite NF2 (adapted from Gutmann et al. 1997):
1. Bilateral vestibular schwannomas; or
2. Family history of NF2 (first-degree relative[s]) plus
(a) unilateral vestibular schwannomas, at age !30
years, or (b) any two of the following: meningioma,
glioma, schwannoma, or juvenile posterior subcap-
sular lenticular opacities/juvenile cortical cataract.
Presumptive or probable NF2 (adapted from Gutmann
et al. 1997):
1. Unilateral vestibular schwannomas, at age !30
years, plus at least one of the following: menin-
gioma, glioma, schwannoma, or juvenile posterior
subcapsular lenticular opacities/juvenile cortical
cataract; or
2. Multiple meningiomas (two or more) plus (a) uni-
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lateral vestibular schwannomas, at age !30 years,
or (b) one of the following: glioma, schwannoma,
or juvenile posterior subcapsular lenticular opaci-
ties/juvenile cortical cataract.
Schwannomatosis
Definite schwannomatosis:
1. Two or more pathologically proved schwannomas;
plus
2. Lack of radiographic evidence of vestibular nerve
tumor, at age 118 years.
Presumptive or probable schwannomatosis:
1. Two or more pathologically proved schwannomas,
without symptoms of eighth-nerve dysfunction, at
age 130 years; or
2. Two or more pathologically proved schwannomas
in an anatomically limited distribution (single limb
or segment of the spine), without symptoms of
eighth-nerve dysfunction, at any age.
For this study, the presence of other NF1- or NF2-
related findings, including neurofibroma, meningioma,
astrocytoma, or ocular abnormality, was not an exclu-
sion criteria.
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